Ara-G hydrate, 98%, inhibitor of DNA synthesis, reagent, for R&D

Name: Ara-G hydrate, 98%, inhibitor of DNA synthesis, reagent, for R&D | 38819-10-2
Brand: J&K Chemical
SKU: JK381488_50_MG
Price: 13.2 USD
Availability: OutOfStock

Cat. No JK381488_50_MG

Vendor: J&K Chemical

Product Information

Product Name

Ara-G hydrate, 98%, inhibitor of DNA synthesis, reagent, for R&D

Brand Name

J&K

Product Number

381488

CAS

38819-10-2

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

135499520

IUPAC Name

2-amino-9-(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl-1H-purin-6-one

InChI Key

NYHBQMYGNKIUIF-FJFJXFQQSA-N

SMILES

C1=NC2=C(N1C@H3C@H(C@@H(C@H(O3)CO)O)O)N=C(NC2=O)N

Safety Information

Storage Condition

Store at 2-8℃

References Data Source From Pubchem

Optimization of upfront therapy for adult acute lymphoblastic leukemia: a paradigm shift toward immunotherapy

Publication Name: Medical oncology (Northwood, London, England)

Publication Date: 2025-10-22

DOI: 10.1007/s12032-025-03093-6

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action

Publication Name: Leukemia

Publication Date: 2025-02-17

DOI: 10.1038/s41375-025-02529-2

Developments in the Fabrication of Nanomaterial-Based Voltammetric Sensors

Publication Name: Advancements in Voltammetry for Biosensing Applications

Publication Date: 2025

DOI: 10.1007/978-981-96-2595-6_6

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

Publication Name: Journal of Hematology & Oncology

Publication Date: 2023-03-16

DOI: 10.1186/s13045-023-01409-5

New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia

Publication Name: Clinical Management of Acute Lymphoblastic Leukemia

Publication Date: 2022

DOI: 10.1007/978-3-030-85147-7_14

Ara-G hydrate, 98%, inhibitor of DNA synthesis, reagent, for R&D

Product Information

General Information

Safety Information

References Data Source From Pubchem

Optimization of upfront therapy for adult acute lymphoblastic leukemia: a paradigm shift toward immunotherapy

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action

Developments in the Fabrication of Nanomaterial-Based Voltammetric Sensors

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia